1. Home
  2. Biosimilar
  Subject:

Biosimilar   New Search

View on DBpedia    View on Wikipedia
Top related subjects:
RELATED SUBJECTS:
The publications listed also have these subjects
Infliximab  5 times
Rheumatoid arthritis  4 times
Pharmacokinetics  3 times
Monoclonal antibody  3 times
Inflammatory bowel disease  3 times
Hormone  3 times
Ulcerative colitis  2 times
PubMed  2 times
Performance status  2 times
Neutropenia  2 times
International law  2 times
Granulocyte colony-stimulating factor  2 times
European Medicines Agency  2 times
Chemotherapy  2 times
Antibody  2 times
Anemia  2 times
Adalimumab  2 times
Tumor necrosis factor alpha  1 time
Transfection  1 time
Single Center  1 time
Rituximab  1 time
Rheumatology  1 time
Protein  1 time
Precision medicine  1 time
Polyethylenimine  1 time
Polyethylene  1 time
Plasmid  1 time
Pharmacovigilance  1 time
Pharmacodynamics  1 time
Ovulation  1 time
Myalgia  1 time
Metabolism  1 time
Memory  1 time
Lymphoma  1 time
Juvenile idiopathic arthritis  1 time
Italy  1 time
International  1 time
Industrial fermentation  1 time
Immunoassay  1 time
Hypoesthesia  1 time
Hematopoietic stem cell  1 time
Growth hormone  1 time
Growth factor  1 time
Gold standard  1 time
Glycan  1 time
Gene  1 time
Etanercept  1 time
Erythropoietin  1 time
Embase  1 time
Electrochemiluminescence  1 time
Eastern Cooperative Oncology Group  1 time
Dialysis  1 time
DNA  1 time
ClinicalTrials.gov  1 time
Clinical trial  1 time
Chronic kidney disease  1 time
Cervical cancer  1 time
Canada  1 time
CD34  1 time
Breast cancer  1 time
Bone density  1 time
Blood transfusion  1 time
Blood lipids  1 time
Biotechnology  1 time
Biomimetics  1 time
Bevacizumab  1 time
Bcl-xL  1 time
B-cell chronic lymphocytic leukemia  1 time
Assisted reproductive technology  1 time
Arthralgia  1 time
Apoptosis  1 time
Apheresis  1 time
Ankylosing spondylitis  1 time
Angiogenesis  1 time
Adverse drug reaction  1 time
Adjuvant  1 time

Publications tagged with this subject: 23

Note: Top 50 publications shown only. Open an item panel to view more info (open all)


1. Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis

2. Clinical Trial Design in Juvenile Idiopathic Arthritis

3. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors

4. CT-P10 (Truxima™): A Rituximab Biosimilar

5. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab

6. Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study

7. A BioDesign Approach to Obtain High Yields of Biosimilars by Anti-apoptotic Cell Engineering: a Case Study to Increase the Production Yield of Anti-TNF Alpha Producing Recombinant CHO Cells

8. Update on Biosimilars in Asia

9. Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap® (XM17), Comparability with Gonal-f®, and Performance/Consistency

10. Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months

11. Physicochemical Properties, Toxicity, and Specific Activity of a Follitropin Alpha Biosimilar

12. Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease

13. Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?

14. A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors

15. Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents

16. Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study

17. Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study

18. Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis

19. Interchangeability of Biosimilars: A European Perspective

20. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community

21. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease

22. Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region

23. Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer


Questions?

Drop us a message.